- Home
- APLT vs LGL Comparison
APLT vs LGL Comparison
Compare APLT & LGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- LGL
- Stock Information
- Founded
- APLT 2016
- LGL 1917
- Country
- APLT United States
- LGL United States
- Employees
- APLT N/A
- LGL N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- LGL Industrial Machinery/Components
- Sector
- APLT Health Care
- LGL Technology
- Exchange
- APLT Nasdaq
- LGL Nasdaq
- Market Cap
- APLT 37.5M
- LGL 34.0M
- IPO Year
- APLT 2019
- LGL N/A
- Fundamental
- Price
- APLT $0.40
- LGL $6.12
- Analyst Decision
- APLT Buy
- LGL
- Analyst Count
- APLT 7
- LGL 0
- Target Price
- APLT $6.10
- LGL N/A
- AVG Volume (30 Days)
- APLT 1.9M
- LGL 4.3K
- Earning Date
- APLT 05-20-2025
- LGL 05-23-2025
- Dividend Yield
- APLT N/A
- LGL N/A
- EPS Growth
- APLT N/A
- LGL 59.20
- EPS
- APLT N/A
- LGL 0.08
- Revenue
- APLT $455,000.00
- LGL $4,292,000.00
- Revenue This Year
- APLT $1,768.13
- LGL N/A
- Revenue Next Year
- APLT $361.28
- LGL N/A
- P/E Ratio
- APLT N/A
- LGL $84.00
- Revenue Growth
- APLT N/A
- LGL 16.69
- 52 Week Low
- APLT $0.30
- LGL $4.86
- 52 Week High
- APLT $10.62
- LGL $7.28
- Technical
- Relative Strength Index (RSI)
- APLT 46.92
- LGL 37.74
- Support Level
- APLT $0.39
- LGL $6.85
- Resistance Level
- APLT $0.44
- LGL $7.08
- Average True Range (ATR)
- APLT 0.04
- LGL 0.16
- MACD
- APLT 0.01
- LGL -0.05
- Stochastic Oscillator
- APLT 45.49
- LGL 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About LGL LGL Group Inc. (The)
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.